[The immunological effectiveness and reactogenicity of the vaccine "HEP-A+B-in-VAC" against hepatitis A and B].
The paper presents the results of field clinical tests of the new Russian vaccine "HEP-A+B-in-VAC" against hepatitis A and B. The vaccine has been found to be safe and to have a weak reactogenicity. After completion of a course of vaccination, seroconversion occurred in 100% of the vaccinated, the high titers of anti-HAV and HBs being found in 90.9 and 72.7% of the volunteers, respectively. A comparative analysis demonstrated that the reactogenicity of the new vaccine was less and its immunogenicity was higher than those in monovaccines against hepatitis A and B when they were co-administered.
Chuĭkova
K I
KI
Gordetskaia
E L
EL
Gorbunov
M A
MA
Maĭdaniuk
A G
AG
Pomytkina
M I
MI
D000293:Adolescent; D000328:Adult; D004334:Drug Administration Schedule; D006506:Hepatitis A / Q000276:immunology*; D035922:Hepatitis A Antibodies / Q000097:blood; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D014611:Vaccination
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines